Episode details
Available for over a year
Ovarian Cancer rates in the UK are amongst the highest in Europe, yet has one of the lowest survival rates. But a new drug, Niraparib, is becoming available in England today and in Wales within the next few weeks, with the aim to provide patients with more time chemo-free. Professor of Medical Oncology, Dr Jonathan Ledermann and ovarian cancer patient, Vanessa Hillary discuss the impact it could have.
Programme Website